Plasma periostin associates significantly with non-vertebral but not vertebral fractures in postmenopausal women: Clinical evidence for the different effects of periostin depending on the skeletal site

Bone

Volumn 81, Issue , 2015, Pages 435-441

  Kim, Beom Jun ^a   Rhee, Yumie ^b   Kim, Chong Hwa ^c   Baek, Ki Hyun ^d   Min, Yong Ki ^e   Kim, Deog Yoon ^f   Ahn, Seong Hee ^a   Kim, Hyeonmok ^a   Lee, Seung Hun ^a   Lee, Sun Young ^g   Kang, Moo Il ^d   Koh, Jung Min ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Sejong General Hospital   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Kyung Hee University Hospital   (South Korea)

^g Asan Institute for Life Sciences   (South Korea)

Author keywords

Bone mineral density; Non vertebral fracture; Osteoporotic fracture; Periostin; Postmenopausal women

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTION FACTOR RUNX2; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; FEMUR NECK; FOREARM FRACTURE; FRACTURE; FRACTURE RISK; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; INTERVIEWER ASSISTED QUESTIONNAIRE; KOREAN (PEOPLE); LUMBAR SPINE; MAJOR CLINICAL STUDY; MIDDLE AGED; NON VERTEBRAL FRACTURE; PELVIS FRACTURE; POSTMENOPAUSE; PREVALENCE; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK; SPINE FRACTURE; SPINE RADIOGRAPHY; AGED; BLOOD; BONE; DIAGNOSTIC IMAGING; DRUG EFFECTS; FEMUR; LUMBAR VERTEBRA; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; RISK FACTOR; SPINAL FRACTURES;

ABSORPTIOMETRY, PHOTON; AGED; BONE AND BONES; BONE DENSITY; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; FEMALE; FEMUR; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; POSTMENOPAUSE; RISK FACTORS; SPINAL FRACTURES;

EID: 84940373576     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.08.014     Document Type: Article

References (39)

1. Choi H.J., Shin C.S., Ha Y.C., Jang S., Jang S., Park C., et al. Burden of osteoporosis in adults in Korea: a national health insurance database study. J. Bone Miner. Metab. 2012, 30:54-58.
2. Melton L.J. Hip fractures: a worldwide problem today and tomorrow. Bone 1993, 14(Suppl. 1):S1-S8.
3. Yi H., Ha Y.C., Lee Y.K., Lim Y.T. National healthcare budget impact analysis of the treatment for osteoporosis and fractures in Korea. J. Bone Metab. 2013, 20:17-23.
4. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001, 285:785-795.
5. Wainwright S.A., Marshall L.M., Ensrud K.E., Cauley J.A., Black D.M., Hillier T.A., et al. Hip fracture in women without osteoporosis. J. Clin. Endocrinol. Metab. 2005, 90:2787-2793.
6. Sanders K.M., Nicholson G.C., Watts J.J., Pasco J.A., Henry M.J., Kotowicz M.A., et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective?. Bone 2006, 38:694-700.
7. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 2008, 19:385-397.
8. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A. Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. Osteoporos. Int. 2008, 19:1395-1408.
9. Bolland M.J., Siu A.T.Y., Mason B.H., Horne A.M., Ames R.W., Grey A.B., et al. Evaluation of the FRAX and Garvan fracture risk calculators in older women. J. Bone Miner. Res. 2011, 26:420-427.
10. Tremollieres F.A., Pouilles J.M., Drewniak N., Laparra J., Ribot C.A., Dargent-Molina P. Fracture risk prediction using BMD and clinical risk factors in early postmenopausal women: sensitivity of the WHO FRAX tool. J. Bone Miner. Res. 2010, 25:1002-1009.
11. Takeshita S., Kikuno R., Tezuka K., Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem. J. 1993, 294(Pt 1):271-278.
12. Horiuchi K., Amizuka N., Takeshita S., Takamatsu H., Katsuura M., Ozawa H., et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J. Bone Miner. Res. 1999, 14:1239-1249.
13. Kashima T.G., Nishiyama T., Shimazu K., Shimazaki M., Kii I., Grigoriadis A.E., et al. Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions. Hum. Pathol. 2009, 40:226-237.
14. Merle B., Garnero P. The multiple facets of periostin in bone metabolism. Osteoporos. Int. 2012, 23:1199-1212.
15. Litvin J., Selim A.H., Montgomery M.O., Lehmann K., Rico M.C., Devlin H., et al. Expression and function of periostin-isoforms in bone. J. Cell. Biochem. 2004, 92:1044-1061.
16. Bonnet N., Standley K.N., Bianchi E.N., Stadelmann V., Foti M., Conway S.J., et al. The matricellular protein periostin is required for Sost inhibition and the anabolic response to mechanical loading and physical activity. J. Biol. Chem. 2009, 284:35939-35950.
17. Gerbaix M., Vico L., Ferrari S.L., Bonnet N. Periostin expression contributes to cortical bone loss during unloading. Bone 2015, 71:94-100.
18. Bonnet N., Conway S.J., Ferrari S.L. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:15048-15053.
19. Rousseau J.C., Sornay-Rendu E., Bertholon C., Chapurlat R., Garnero P. Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J. Clin. Endocrinol. Metab. 2014, 99:2533-2539.
20. Nathan M., Pope M.H., Grobler L.J. Osteophyte formation in the vertebral column: a review of the etiologic factors - Part II. Contemp. Orthop. 1994, 29:113-119.
21. Kiel D. Assessing vertebral fractures. National Osteoporosis Foundation Working Group on Vertebral Fractures. J. Bone Miner. Res. 1995, 10:518-523.
22. Genant H.K., Wu C.Y., van Kuijk C., Nevitt M.C. Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 1993, 8:1137-1148.
23. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
24. Bonnet N., Gineyts E., Ammann P., Conway S.J., Garnero P., Ferrari S. Periostin deficiency increases bone damage and impairs injury response to fatigue loading in adult mice. PLoS One 2013, 8.
25. Nakazawa T., Nakajima A., Seki N., Okawa A., Kato M., Moriya H., et al. Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J. Orthop. Res. 2004, 22:520-525.
26. Meier C., Nguyen T.V., Center J.R., Seibel M.J., Eisman J.A. Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study. J. Bone Miner. Res. 2005, 20:579-587.
27. Vasikaran S., Eastell R., Bruyere O., Foldes A.J., Garnero P., Griesmacher A., et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 2011, 22:391-420.
28. Garnero P. New developments in biological markers of bone metabolism in osteoporosis. Bone 2014, 66:46-55.
29. Kii I., Amizuka N., Minqi L., Kitajima S., Saga Y., Kudo A. Periostin is an extracellular matrix protein required for eruption of incisors in mice. Biochem. Biophys. Res. Commun. 2006, 342:766-772.
30. Takayama G., Arima K., Kanaji T., Toda S., Tanaka H., Shoji S., et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 2006, 118:98-104.
31. Maruhashi T., Kii I., Saito M., Kudo A. Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase. J. Biol. Chem. 2010, 285:13294-13303.
32. Bonnet N., Lesclous P., Saffar J.L., Ferrari S. Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice. PLoS One 2013, 8.
33. Kii I., Nishiyama T., Li M., Matsumoto K., Saito M., Amizuka N., et al. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J. Biol. Chem. 2010, 285:2028-2039.
34. Liu A.Y., Zheng H., Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. 2014, 37:150-156.
35. Tilman G., Mattiussi M., Brasseur F., van Baren N., Decottignies A. Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells. Mol. Cancer 2007, 6:80.
36. Contie S., Voorzanger-Rousselot N., Litvin J., Clezardin P., Garnero P. Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int. J. Cancer 2011, 128:352-360.
37. Ruan K., Song G., Ouyang G. Role of hypoxia in the hallmarks of human cancer. J. Cell. Biochem. 2009, 107:1053-1062.
38. Shao R., Bao S., Bai X., Blanchette C., Anderson R.M., Dang T., et al. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol. Cell. Biol. 2004, 24:3992-4003.
39. Sasaki H., Yu C.Y., Dai M., Tam C., Loda M., Auclair D., et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res. Treat. 2003, 77:245-252.